{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:10:28Z","timestamp":1782526228123,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.encep.2008.04.004","type":"journal-article","created":{"date-parts":[[2008,8,16]],"date-time":"2008-08-16T05:13:33Z","timestamp":1218863613000},"page":"400-408","source":"Crossref","is-referenced-by-count":10,"title":["Efficacit\u00e9 et tol\u00e9rance de l\u2019escitalopram dans les troubles anxieux\u00a0: revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"34","author":[{"given":"A.","family":"Pelissolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2008.04.004_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1461145705005973","article-title":"Prevention of relapse in generalized anxiety disorder by escitalopram treatment","volume":"9","author":"Allgulander","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2008.04.004_bib2","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1185\/030079907X226087","article-title":"Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial","volume":"23","author":"Allgulander","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"suppl. 1","key":"10.1016\/j.encep.2008.04.004_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2005.01202.x","article-title":"Cost of disorders of the brain in Europe","volume":"12","author":"Andlin-Sobocki","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.encep.2008.04.004_bib4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalized anxiety disorder: randomised, placebo-controlled, double-blind study","volume":"189","author":"Baldwin","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1K089","article-title":"Escitalopram therapy for major depression and anxiety disorders","volume":"41","author":"Baldwin","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.encep.2008.04.004_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archpsyc.64.8.903","article-title":"Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life","volume":"64","author":"Beesdo","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10401230590932326","article-title":"A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder","volume":"17","author":"Bielski","year":"2005","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","article-title":"Clomipramine in the treatment of patients with obsessive-compulsive disorder","volume":"48","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib9","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.v66n1115","article-title":"Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder","volume":"66","author":"Davidson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.encep.2008.04.004_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00023210-200620090-00010","article-title":"Escitalopram: a review of its use in the management of anxiety disorders","volume":"20","author":"Dhillon","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2008.04.004_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.euroneuro.2005.04.002","article-title":"Size and burden of social phobia in Europe","volume":"15","author":"Fehm","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2008.04.004_bib13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.euroneuro.2006.11.005","article-title":"Escitalopram prevents relapse of obsessive-compulsive disorder","volume":"17","author":"Fineberg","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2008.04.004_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2004.11.011","article-title":"Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials","volume":"87","author":"Goodman","year":"2005","journal-title":"J Affect Disord"},{"key":"10.1016\/j.encep.2008.04.004_bib15","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Affections psychiatriques de longue dur\u00e9e\u00a0: troubles anxieux graves. Paris: HAS www.has-sante.fr\u00a0; 2007."},{"key":"10.1016\/j.encep.2008.04.004_bib16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","article-title":"Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study","volume":"19","author":"Lader","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.encep.2008.04.004_bib18","doi-asserted-by":"crossref","unstructured":"Lecrubier Y, Dolberg OT, Andersen HF, et al. Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder. Eur Arch Psychiatry Clin Neurosci (in press) 2007 Dec 14. [Epub ahead of print].","DOI":"10.1007\/s00406-007-0771-x"},{"issue":"suppl. 3","key":"10.1016\/j.encep.2008.04.004_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00004850-199606003-00007","article-title":"Comorbidity and social phobia: clinical and epidemiological issues","volume":"11","author":"Lepine","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2008.04.004_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/(SICI)1520-6394(2000)11:3<87::AID-DA1>3.0.CO;2-9","article-title":"Why take social anxiety disorder seriously?","volume":"11","author":"Lepine","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.encep.2008.04.004_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0013-7006(05)82385-1","article-title":"Pr\u00e9valence et comorbidit\u00e9 des troubles psychiatriques dans la population g\u00e9n\u00e9rale fran\u00e7aise","volume":"31","author":"Lepine","year":"2005","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2008.04.004_bib22","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","article-title":"A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder","volume":"66","author":"Montgomery","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib23","first-page":"510","article-title":"\u00c9pid\u00e9miologie des troubles anxieux en psychiatrie lib\u00e9rale\u00a0: pr\u00e9valences, comorbidit\u00e9 et retentissement (\u00e9tude Delta)","volume":"28","author":"Pelissolo","year":"2002","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2008.04.004_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0013-7006(06)76143-7","article-title":"Les phobies sociales en psychiatrie\u00a0: caract\u00e9ristiques cliniques et modalit\u00e9s de prise en charge (\u00e9tude Phoenix)","volume":"32","author":"Pelissolo","year":"2006","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2008.04.004_bib25","series-title":"L\u2019anxi\u00e9t\u00e9 g\u00e9n\u00e9ralis\u00e9e","first-page":"123","article-title":"Retentissement de l\u2019anxi\u00e9t\u00e9 g\u00e9n\u00e9ralis\u00e9e sur l\u2019adaptation sociale","author":"P\u00e9lissolo","year":"2005"},{"key":"10.1016\/j.encep.2008.04.004_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.jcp.0000195383.96383.25","article-title":"New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram","volume":"26","author":"Rampello","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2008.04.004_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","article-title":"Escitalopram, the S\u2013(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities","volume":"167","author":"Sanchez","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.encep.2008.04.004_bib28","first-page":"461","article-title":"Effets du escitalopram sur les sympt\u00f4mes anxieux dans la depression","volume":"28","author":"Spadone","year":"2002","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2008.04.004_bib29","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(02)09620-4","article-title":"Obsessive-compulsive disorder","volume":"360","author":"Stein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.encep.2008.04.004_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10401230590932335","article-title":"Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes","volume":"17","author":"Stein","year":"2005","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.encep.2008.04.004_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.encep.2008.04.004_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/da.20043","article-title":"Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions","volume":"20","author":"Stein","year":"2004","journal-title":"Depress Anxiety"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700608001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700608001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T07:18:36Z","timestamp":1557731916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700608001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0013700608001498"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2008.04.004","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}